Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868620035Aexternal-prioritypatent/GB8620035D0/en
Application filed by Sandoz LtdfiledCriticalSandoz Ltd
Publication of MY102687ApublicationCriticalpatent/MY102687A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
NASAL PHARMACEUTICAL COMPOSITIONS COMPRISING THE SOMATOSTATIN ANALOGUE OCTREOTIDE AND THE USE OF OCTREOTIDE IN THE MANUFACTURE OF NASAL PHARMACEUTICAL COMPOSITIONS ARE DESCRIBED. THIS IS A NOVEL MEANS OF ADMINISTRATION FOR OCTREOTIDE WHICH PERMITS EFFECTIVE LONG TERM TREATMENT WITH NO GREAT INCONVENIENCE TO THE PATIENT COMPARED WITH REPEATED PARENTERAL ADMINISTRATIONS.
MYPI87001357A1986-08-181987-08-17Novel galenical comprising a somatostatin formulations.
MY102687A
(en)
Pharmaceutical composition for oral administration containing, on the one hand, as active principle the 9-alpha,11-beta dichloro-16-alpha methyl 21-oxycarbonyldicyclohexylmethyloxy pregna-1,4-diene 3,20-dione and, on the other hand, an inert pharmaceutical excipient which is able to permit the activity of the product in the rectum or in the colon and the utilization of the active principle in the preparation of such a pharmaceutical composition